Mar 05, 2021
Immutep Expands Part B of TACTI-002 Study
Jan 26, 2021
Immutep Announces Advancement Of Phase II Trial For Eftilagimod Alpha In Covid-19 Patients To Randomised Portion Of The Study
Jan 21, 2021
Immutep Quarterly Activities Report
Ulcerative Colitis Phase II Study of GSK2831781 Discontinued
Jan 05, 2021
Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study
Dec 28, 2020
Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor
Dec 16, 2020
Immutep Upscales Efti Manufacturing
Dec 15, 2020
Immutep Operational Update
Dec 08, 2020
Immutep’s Chinese Partner EOC Pharma to Start Phase II Metastatic Breast Cancer Study
Immutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast Cancer
Nov 17, 2020
Immutep Announces Expansion of TACTI-002 Collaboration Trial
Immutep Completes a A$29.6 Million Placement to Accelerate and Broaden its Clinical Development
